• 1.

    Reidy K, et al.. Molecular mechanisms of diabetic kidney disease. J Clin Invest 2014; 124:23332340.

  • 2.

    Gregg EW, Williams DE, Geiss L. Changes in diabetes-related complications in the United States. N Engl J Med 2014; 371:286287.

  • 3.

    Tervaert TW, et al.. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010; 21:556563.

  • 4.

    National Kidney Foundation. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 Update. Am J Kidney Dis 2015; 66:884930.

    • Search Google Scholar
    • Export Citation
  • 5.

    Perkins BA, et al.. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348:22852293.

  • 6.

    Sharma SG, et al.. The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol 2013; 8:17181724.

  • 7.

    Handelsman Y, et al.. American Association of Clinical Endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. Endocr Pract 2015; 21[Suppl 1]:187.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Marso SP, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311322.

  • 9.

    Wanner C, et al.. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375:323334.

  • 10.

    Zinman B, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:21172128.

  • 11.

    Heerspink HJ, et al.. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2017; 28(1):368375.

    • Crossref
    • Search Google Scholar
    • Export Citation

Diabetic Kidney Disease

  • 1 Caroline Gluck, MD, is a Pediatric Nephrology Fellow in the Division of Nephrology at the Children’s Hospital of Philadelphia, and Katalin Susztak, MD, PhD, is affiliated with the Renal Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Restricted access
Kidney disease remains a leading cause of mortality in patients with diabetes

Diabetes is pandemic. Globally, diabetes affects up to half a billion people. In the US, one in 10 people have diabetes. Moreover, for Americans born in the year 2000, the lifetime risk of diabetes is a staggering 25% to 45%.

Diabetes care has significantly improved over the past few decades. Patient education, support, provider role changes, and telemedicine are consistently shown to improve glycemic indices. In response to the diabetes epidemic, the rate of diabetes drug approvals has accelerated. Since January 2013, nine new diabetes products have been